【摘要】 目的：研究贝伐珠单抗联合化疗治疗对转移性结直肠癌(MCRC)患者的肿瘤标志物及机体免疫的影响。方法：选取2021年3月—2022年12月经九江市第一人民医院确诊为MCRC的患者78例，按随机数字表法分组，每组39例。对照组仅接受FOLFOX-6方案化疗，观察组基于对照组化疗条件施加贝伐珠单抗靶向治疗，比较两组方案近期疗效、治疗前后肿瘤标志物[癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、生殖细胞特异性蛋白DDX4(DDX4)]和机体免疫状况[CD3~+、CD4~+、自然杀伤细胞(NK)]。结果：观察组客观有效率、疾病控制率均高于对照组(P<0.05)。治疗后，观察组3项肿瘤标志物(CEA、CA19-9及DDX4)检测值均低于对照组(P<0.05)。治疗后，观察组3项机体免疫指标(CD3~+、CD4~+及NK)检测值均高于对照组(P<0.05)。结论：贝伐珠单抗联合化疗治疗能够提升MCRC患者的近期治疗效果，降低肿瘤标志物水平，或与其可调节机体免疫状况有关。更多还原

【Abstract】 Objective:To study the effect of Bevacizumab combined with chemotherapy on tumor markers and body immunity in patients with metastatic colorectal cancer (MCRC).Method:A total of 78 patients diagnosed with MCRC in Jiujiang NO.1 People’s Hospital from March 2021 to December 2022 were selected and divided into groups using a random number table method,with 39 patients in each group.The control group only received FOLFOX-6 chemotherapy,and the observation group received Bevacizumab targeted therapy based on the chemotherapy conditions of the control group.The short-term efficacy,tumor markers[carcinoembryonic antigen (CEA),carbohydrate antigen 19-9 (CA19-9),germ cell specific protein DDX4 (DDX4)]and body immune status[CD3~+,CD4~+,natural killer cell (NK)]before and after treatment of the two groups were compared.Result:The objective effective rate and disease control rate of the observation group were higher than those of the control group (P<0.05).After treatment,the detection values of three tumor markers (CEA,CA19-9 and DDX4) in the observation group were lower than those in the control group (P<0.05).After treatment,the detection values of three immune indicators (CD3~+,CD4~+ and NK) in the observation group were higher than those in the control group (P<0.05).Conclusion:Bevacizumab combined with chemotherapy can improve the short-term therapeutic effect of MCRC patients,reduce the levels of tumor markers,or it may be related to the regulation of immune status of the body.更多还原